Solid Tumors News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Pembrolizumab Plus SBRT Active in Advanced Solid Tumors - OncLive



OncLive
 
Pembrolizumab Plus SBRT Active in Advanced Solid Tumors 
OncLive
The mean percent change in tumor diameter was ?21.7% (standard deviation[SD], 24.3%) for irradiated metastases versus 1.7% (SD, 46.3%) for nonirradiated metastases (P = .0008). When investigators compared tumor control between irradiated and ...

 


Kinase inhibitor larotrectinib shows durable anti-tumor abilities - Medical Xpress



Medical Xpress
 
Kinase inhibitor larotrectinib shows durable anti-tumor abilities 
Medical Xpress
"In this series of studies, larotrectinib had rapid, potent and durable anti-tumor activity in children and adults who had solid tumors with TRK fusions without regard to patient age, tumor tissue and fusion status," said Hong. "Our data not only ...
Larotrectinib active, safe in certain fusion-positive cancers Healio
Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine GlobeNewswire (press release)

all 5 news articles » 


Alpelisib Active in PIK3CA-Altered Solid Tumors - OncLive



OncLive
 
Alpelisib Active in PIK3CA-Altered Solid Tumors 
OncLive
Alpelisib (BYL719) induced a disease control rate (DCR) of 58.2% in patients with advanced solid tumors, according to results from a phase Ia study published in the Journal of Clinical Oncology. Treatment with the oral PIK3CA selective inhibitor led to ...

 


Cancer Vaccines May Overhaul Cancer Therapy in the Next Decade - Singularity Hub



Singularity Hub
 
Cancer Vaccines May Overhaul Cancer Therapy in the Next Decade 
Singularity Hub
The term ?silver bullet? gets tossed around a lot, but cancer vaccines are just that. They don't just seek to prevent cancers from forming. In many cases, these vaccines also treat tumors already within the body. The area is moving fast?as two recent ...
Can you vaccinate yourself against cancer? - CNN - CNN.com CNN

all 6 news articles » 


Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors - GlobeNewswire (press release)



GlobeNewswire (press release)
 
Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors 
GlobeNewswire (press release)
SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the ...
Fate Therapeutics (FATE) Stocks Latest Headlines - Barchart.com Barchart.com

all 27 news articles » 


Erytech doubles down on solid tumor trials for red cell drug therapy - FierceBiotech



FierceBiotech
 
Erytech doubles down on solid tumor trials for red cell drug therapy 
FierceBiotech
Erytech doubles down on solid tumor trials for red cell drug therapy. by Phil Taylor |. Feb 13, 2018 10:00am. Red blood cells. If successful, the trial could open up a big market for red blood cell-encapsulated L-asparaginase. Share Facebook Twitter ...
ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase GlobeNewswire (press release)
Erytech's 'Armed' Red Blood Cells Will be Tested Against Triple Negative Breast Cancer Labiotech.eu (blog)

all 3 news articles » 


Bicycle's First Peptide-Toxin Conjugate Enters the Clinic for Solid Tumors - Labiotech.eu (blog)



Bicycle's First Peptide-Toxin Conjugate Enters the Clinic for Solid Tumors 
Labiotech.eu (blog)
A collaboration between Bicycle Therapeutics and Cancer Research UK has yielded its first peptide to enter clinical trials for solid tumors. Bicycle Therapeutics, the pioneer of the bicyclic peptide platform, has dosed the first patient in a Phase I ...

and more » 


Building on BRCA Test Launch, NGeneBio Rolls Out NGS Panels for Solid Tumors, Hematological Cancers - GenomeWeb



Building on BRCA Test Launch, NGeneBio Rolls Out NGS Panels for Solid Tumors, Hematological Cancers 
GenomeWeb
NEW YORK (GenomeWeb) ? Korean molecular diagnostics company NGeneBio recently introduced two new next-generation sequencing-based panels for cancer and aims to achieve European regulatory clearance for both by year end. The Seoul-based company also ...

 


As Cancer Immune Therapies Advance, 4 Biomarker Trends To Watch - Life Science Leader Magazine



Life Science Leader Magazine
 
As Cancer Immune Therapies Advance, 4 Biomarker Trends To Watch 
Life Science Leader Magazine
Investigations into the tumor microenvironment at a genetic level seek to determine whether genetic changes within the tumor microenvironment can guide the design of cancer immunotherapeutics. Unlike predictive or prognostic biomarkers, immune targets ...

and more » 


Sophia Genetics Looks to Marry Imaging, Genomic Analysis for MDx - GenomeWeb



Sophia Genetics Looks to Marry Imaging, Genomic Analysis for MDx 
GenomeWeb
CHICAGO (GenomeWeb) ? Machine learning in genomic medicine and molecular diagnosis got a boost last month when Sophia Genetics announced that its technology now can scan medical images to predict the evolution of solid tumors. By combining this ...

and more »